A research team comprised of pharmacists across the HM System specializing in oncology and formulary management (Isha Rana, PharmD; Zhili “Lilly” Fu, PharmD, BCOP; Erika N. Brown, MS, PharmD, BCOP; Rodrigo De La Torre, PharmD; Cynthia El Rahi, PharmD BCOP; Hanna Zaghloul, PharmD, BCOP) submitted a proposal for an investigator-initiated study in response to the National Comprehensive Cancer Network (NCCN) and Pfizer Global Medical Grants request for proposals for adoption of biosimilars in oncology.
Their proposal, titled “Impact of Discordant Preferred Drug Status between Hospitals and Payers for Chemotherapeutic Biosimilars,” was approved for funding by Pfizer and NCCN.
The team was awarded a $19,500 grant to assess the multifaceted impact to health-systems when payer policies designate a preferred product that differs from the health-system formulary preferred product, specifically for trastuzumab and bevacizumab.
Congratulations to this team on a job well done.
Leave a Reply